March 26 (Reuters) - Denmark's Novo Nordisk said on Thursday it had decided to submit interim analysis data from a clinical trial of its crucial new insulin drug Tresiba to U.S. regulators within the ...
Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp ...
New studies on the effectiveness of Novo Nordisk's newest insulin have not been enough to convince Express Scripts to give it preferred status on its formulary. New studies on the effectiveness of ...
When announcing in November the discontinuation of Levemir in the U.S., Novo Nordisk cited manufacturing constraints, reduced patient access and available alternatives -- including its other ...
Gov. Gavin Newsom said Thursday that California will begin selling affordable insulin under its own label on Jan. 1, nearly three years after he first announced a partnership to sell state-branded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback